Oxurion NV — Director's Dealing 2022

Dec 7, 2022

Oxurion Receives Transparency Notifications from Negma Group

Leuven, BELGIUM, Boston, MA, US – December 7, 2022 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received transparency notification on December 5 from Negma Group Ltd. indicating that as of November 29, it held 44,900,740 shares of the then outstanding 269,264,838 shares, and therefore crossed below the 10% threshold by virtue of acquisition of voting securities. See Annex 1

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Oxurion NV	US
Tom Graney	Conway Communications
Chief Executive Officer	Beth Kurth
Tel: +32 16 75 13 10	bkurth@conwaycommsir.com
tom.graney@oxurion.com

For further information please contact:

Michael Dillen	ICR Westwicke
Chief Business Officer	Christopher Brinzey
Tel: +32 16 75 13 10	Tel: +1 617 835 9304
michael.dillen@oxurion.com	Chris.Brinzey@westwicke.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

________

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Final
2) Issuer
	Name OXURION
Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A parent undertaking or a controlling person
5) Persons subject to the notification requirement
	Name			Address (for legal entities)
	Elaf Gassam
	Negma Group Investment Ltd.			Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubal (United Arab Emirates)
	Negma Group Ltd.		(slands)	Craigmuir chambers, Road Town, Tortola, VG 1110 (British Virgin
6) Persons that dispose of voting rights (only to be filed in it art. 7 of the Law applies)
	Name			Address (for legal entities)
w 7) Date on which the threshold is crossed	Please confinue entering the Information in part $N$ concerning the persons referred to in Sections 6 and 8			Part II
			29/11/2022 (DO/MWYYYYY)
8) Threshold that is crossed (in %)
		$20\,$
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		269,264,838
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification			After the transaction
	# of voting rights			# of voting rights		% of voting rights
Holders of voting rights			Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Eaf Gassam	O		$\circ$		0.00%
Negma Group Investment Ltd.	$\Box$		$\circ$		0.00%
Negma Group Ltd. Subtotal	65,537,782 65,537,782		44,900,740 44,900,740		16.68% 16.68%

TOTAL	44,900,740	18.88%	0.00%
Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".

# of voting rights that may be BASIN' DROOM DV CONTROL Holders of equivalent Exerolse period or Expiration date % of voting rights Type of financial instrument acquired if the financial instruments date Instrument is bealonexe
				Sottlement

CALCULATE 44,900,740

16,68%

11) Full chain of controlled undertakings through which the holding is effectively held, it applicable

Done at Dubai, United Arab Emirates
On	05/12/2022 (DO/MWYYYYY)
Name & capacity Elaf Gassam, Director		Signature